What are the recommended next steps for managing a patient with severe migraines who is experiencing constipation and rebound headaches on daily atogepant (Quilipta), has inadequate response to rizatriptan rescue, and has failed propranolol, topiramate, and sumatriptan?

Switch Atogepant to a Different Preventive and Optimize Acute Treatment

You should discontinue atogepant (Quilipta) due to intolerable constipation and likely medication-overuse headache, transition to an alternative preventive therapy, and switch the failing rizatriptan to a different triptan combined with an NSAID for acute treatment.

Immediate Actions

Address Medication Overuse Headache

The severe migraines when missing atogepant doses strongly suggest medication-overuse headache (MOH) or rebound phenomenon. While atogepant itself is a preventive, the pattern described—worsening with missed doses and declining rizatriptan efficacy—indicates potential MOH from the acute medication 1. Rizatriptan use should be limited to ≤10 days per month to avoid transformation to chronic migraine 1.

Optimize Acute Treatment First

Before changing preventives, fix the acute treatment strategy:

Switch from rizatriptan monotherapy to combination therapy:

• Try a different triptan (eletriptan, zolmitriptan, or almotriptan) since patients who fail one triptan may respond to another within the same class 1
• Combine the triptan with an NSAID (naproxen 500-550mg or ibuprofen 400-800mg) or acetaminophen—this combination is superior to monotherapy and is the preferred first-line approach 1
• Instruct the patient to treat early in the attack and limit use to ≤2 days per week to prevent MOH 1

If combination therapy fails, consider acute CGRP antagonists (gepants) like rimegepant, ubrogepant, or zavegepant for rescue 1. These are recommended when triptan/NSAID combinations are inadequate 1.

Preventive Treatment Strategy

Discontinue Atogepant

While atogepant is effective for prevention 2, 3, 4, 5, the constipation is a well-documented adverse effect occurring in 10-11% of patients 3, 4, 5. The "severe migraines when missing doses" likely represents either:

1. Return of baseline migraine frequency (expected with any preventive)
2. Possible rebound from overusing acute medications
3. Inadequate preventive efficacy

Given the intolerable side effect and the patient's treatment-resistant profile, switching is warranted.

Next Preventive Options

First choice: Try a different CGRP pathway medication

• Erenumab, fremanezumab, galcanezumab, or eptinezumab (anti-CGRP monoclonal antibodies) 6
• These have different mechanisms (blocking the ligand vs. receptor) and may be better tolerated
• Injectable/IV formulations avoid GI side effects
• Particularly effective in chronic migraine and medication overuse headache 7

Second choice: OnabotulinumtoxinA

• Especially if the patient has chronic migraine (≥15 headache days/month) 6
• No systemic GI side effects
• Effective even with prior preventive failures

Third choice: Consider other oral preventives 6:

• Candesartan or lisinopril (ARB/ACE inhibitor)—well-tolerated, no GI issues
• Amitriptyline—but avoid if constipation is a major concern
• Avoid topiramate given prior failure

Important Caveat About CGRP Medications

The patient has already failed one CGRP receptor antagonist (atogepant). While prior anti-CGRP exposure predicts poorer response to subsequent CGRP therapies 7, many patients still achieve meaningful benefit, particularly if the reason for discontinuation was tolerability rather than lack of efficacy 7. Since this patient stopped due to side effects (not inefficacy), trying a monoclonal antibody is reasonable.

Clinical Pitfalls to Avoid

1. Don't continue atogepant with laxatives—while constipation can be managed, the patient is already experiencing poor quality of life from this side effect

2. Don't add another preventive on top of atogepant—no evidence supports combination preventive therapy with atogepant plus another agent 6

3. Don't use opioids or butalbital—these are explicitly contraindicated and dramatically increase MOH risk 1, 8

4. Address the acute medication overuse immediately—even the best preventive will fail if the patient continues overusing acute medications 8

5. Set realistic expectations—with 3 prior preventive failures (propranolol, topiramate, sumatriptan as acute), this is a treatment-resistant case requiring patience and possibly 2-3 months to see preventive benefit 6

Practical Implementation

1. Week 1-2: Taper atogepant if needed (though abrupt discontinuation is generally safe), start new preventive (e.g., erenumab 70mg monthly)
2. Simultaneously: Switch acute treatment to eletriptan 40mg + naproxen 500mg, strictly limit to 2 days/week
3. Weeks 4-12: Monitor monthly migraine days; preventive effects may take 4-8 weeks 6
4. If inadequate response at 3 months: Switch to onabotulinumtoxinA or try a different CGRP antibody

The combination of fixing the acute treatment strategy (triptan + NSAID, limited frequency) and switching to a better-tolerated preventive should significantly improve this patient's migraine control and quality of life 1, 6.